References
- Zhang Y, Kang SA, Mukherjee T, et al. Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry 2007;46(1):145–155. doi:https://doi.org/10.1021/bi0620095.
- Panozzo C, Nawara M, Suski C, et al. Aerobic and anaerobic NAD + metabolism in Saccharomyces cerevisiae. FEBS Lett 2002;517(1–3):97–102.
- Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396(1):203–213.
- Metz R, DuHadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67(15):7082–7087.
- Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J Mol Med (Berl) 2007;85(12):1351–1359. doi:https://doi.org/10.1007/s00109-007-0229-7.
- Lanz TV, Williams SK, Stojic A, et al. Tryptophan-2,3-dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Sci Rep 2017;7:41271. doi:https://doi.org/10.1038/srep41271.
- Sugimoto H, Oda S-I, Otsuki T, et al. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006;103(8):2611–2616. doi:https://doi.org/10.1073/pnas.0508996103.
- Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105(4):1815–1822.
- Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72(21):5435–5440.
- Mellor A. Indoleamine 2, 3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 2005;338(1):20–24.
- Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22(5):633–642. doi:https://doi.org/10.1016/j.immuni.2005.03.013.
- Moon YW, Hajjar J, Hwu P, et al. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 2015;3(1):51. doi:https://doi.org/10.1186/s40425-015-0094-9.
- Yamamoto Y, Yamasuge W, Imai S, et al. Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling. Sci Rep 2018;8(1):15917. doi:https://doi.org/10.1038/s41598-018-34166-4.
- Prendergast GC, Metz R, Muller AJ, et al. IDO2 in immunomodulation and autoimmune disease. Front Immunol 2014;5:585. doi:https://doi.org/10.3389/fimmu.2014.00585.
- Ball HJ, Yuasa HJ, Austin CJ, et al. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 2009;41(3):467–471. doi:https://doi.org/10.1016/j.biocel.2008.01.005.
- Bilir C, Sarisozen C. Indoleamine 2,3-dioxygenase (IDO): only an enzyme or a checkpoint controller? J Oncol Sci 2017;3(2):52–56.
- Yuasa HJ, Ball HJ, Ho YF, et al. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp Biochem Physiol B Biochem Mol Biol 2009;153(2):137–144. doi:https://doi.org/10.1016/j.cbpb.2009.02.002.
- Heitger A. Regulation of expression and function of IDO in human dendritic cells. Curr Med Chem 2011;18(15):2222–2233. doi:https://doi.org/10.2174/092986711795656018.
- Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009;58(1):153–157.
- Metz R, Smith C, DuHadaway JB, et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol 2014;26(7):357–367. doi:https://doi.org/10.1093/intimm/dxt073.
- Merlo LM, DuHadaway JB, Grabler S, et al. IDO2 modulates T cell-dependent autoimmune responses through a B cell-intrinsic mechanism. J Immunol 2016;196(11):4487–4497. doi:https://doi.org/10.4049/jimmunol.1600141.
- Trabanelli S, Očadlíková D, Ciciarello M, et al. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol 2014;192(3):1231–1240.
- Merlo LM, Grabler S, DuHadaway JB, et al. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clin Immunol 2017;179:8–16. doi:https://doi.org/10.1016/j.clim.2017.01.016.
- Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013;34(3):137–143. doi:https://doi.org/10.1016/j.it.2012.10.001.
- Witkiewicz AK, Costantino CL, Metz R, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009;208(5):781–787.
- Mbongue JC, Nicholas DA, Zhang K, et al. Induction of indoleamine 2, 3-dioxygenase in human dendritic cells by a cholera toxin B subunit-proinsulin vaccine. PLoS One 2015;10(2):e0118562.
- Tas SW, Vervoordeldonk MJ, Hajji N, et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 2007;110(5):1540–1549.
- Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007;7(10):817–823. doi:https://doi.org/10.1038/nri2163.
- Manches O, Fernandez MV, Plumas J, et al. Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci USA 2012;109(35):14122–14127. doi:https://doi.org/10.1073/pnas.1204032109.
- Ling W, Zhang J, Yuan Z, et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res 2014;74(5):1576–1587.
- Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005;25(1):20–30. doi:https://doi.org/10.1089/jir.2005.25.20.
- Su J, Chen X, Huang Y, et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ 2014;21(3):388–396. doi:https://doi.org/10.1038/cdd.2013.149.
- Konan KV, Taylor MW. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996;271(32):19140–19145. doi:https://doi.org/10.1074/jbc.271.32.19140.
- Orabona C, Puccetti P, Vacca C, et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006;107(7):2846–2854.
- Orabona C, Pallotta MT, Volpi C, et al. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 2008;105(52):20828–20833. doi:https://doi.org/10.1073/pnas.0810278105.
- Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011;12(9):870–878. doi:https://doi.org/10.1038/ni.2077.
- Stockinger B, Hirota K, Duarte J, et al. External influences on the immune system via activation of the aryl hydrocarbon receptor. Semin Immunol 2011;23(2):99–105.
- Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010;185(6):3190–3198.
- Nguyen NT, Kimura A, Nakahama T, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 2010;107(46):19961–19966.
- Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478(7368):197–203.
- Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA 2012;109(7):2497–2502. doi:https://doi.org/10.1073/pnas.1113873109.
- Kilberg MS, Shan J, Su N. ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab 2009;20(9):436–443. doi:https://doi.org/10.1016/j.tem.2009.05.008.
- Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest 2012;41(6–7):738–764.
- Mbongue J, Nicholas D, Firek A, Langridge W. The role of dendritic cells in tissue-specific autoimmunity. J Immunol Res 2014;2014:1–17.
- Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176(11):6752–6761.
- Dalton DK, Noelle RJ. The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 2012;61(9):1511–1520. doi:https://doi.org/10.1007/s00262-012-1246-0.
- Cobbold SP, Adams E, Farquhar CA, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA 2009;106(29):12055–12060. doi:https://doi.org/10.1073/pnas.0903919106.
- Shi Y, Su J, Roberts AI, et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012;33(3):136–143. doi:https://doi.org/10.1016/j.it.2011.11.004.
- Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014;15(11):1009–1016. doi:https://doi.org/10.1038/ni.3002.
- Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ 2018;25(7):1209–1223. doi:https://doi.org/10.1038/s41418-017-0006-2.
- Choi H, Lee RH, Bazhanov N, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 2011;118(2):330–338.
- Danchuk S, Ylostalo JH, Hossain F, et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther 2011;2(3):27. doi:https://doi.org/10.1186/scrt68.
- Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003;116(Pt 10):1863–1873. doi:https://doi.org/10.1242/jcs.00407.
- Mittal M, Tiruppathi C, Nepal S, et al. TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci USA 2016;113(50):E8151–E8158.
- Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103(12):4619–4621. doi:https://doi.org/10.1182/blood-2003-11-3909.
- Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009;27(8):1954–1962. doi:https://doi.org/10.1002/stem.118.
- Chiarugi A, Meli E, Moroni F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J Neurochem 2001;77(5):1310–1318.
- Okuda S, Nishiyama N, Saito H, et al. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci USA 1996;93(22):12553–12558. doi:https://doi.org/10.1073/pnas.93.22.12553.
- Suh H-S, Zhao M-L, Rivieccio M, et al. Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response. J Virol 2007;81(18):9838–9850.
- Mbongue JC, Nicholas DA, Torrez TW, et al. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines 2015;3(3):703–729. doi:https://doi.org/10.3390/vaccines3030703.
- Zaher SS, Germain C, Fu H, et al. 3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 2011;52(5):2640–2648.
- Pop SM, Wong CP, He Q, et al. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007;56(5):1395–1402.
- Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003;24(5):242–248.
- Terness P, Bauer TM, Röse L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196(4):447–457.
- Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196(4):459–468. doi:https://doi.org/10.1084/jem.20020121.
- Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281(5380):1191–1193.
- Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002;9(10):1069–1077. doi:https://doi.org/10.1038/sj.cdd.4401073.
- Mellor AL, Lemos H, Huang L. Indoleamine 2,3-dioxygenase and tolerance: where are we now? Front Immunol 2017;8:1360. doi:https://doi.org/10.3389/fimmu.2017.01360.
- Sundrud MS, Koralov SB, Feuerer M, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009;324(5932):1334–1338. doi:https://doi.org/10.1126/science.1172638.
- Keller TL, Zocco D, Sundrud MS, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol 2012;8(3):311–317. doi:https://doi.org/10.1038/nchembio.790.
- Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase. J Clin Invest 2007;117(9):2570–2582.
- Chen W, Liang X, Peterson AJ, et al. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008;181(8):5396–5404. doi:https://doi.org/10.4049/jimmunol.181.8.5396.
- Manches O, Munn D, Fallahi A, et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest 2008;118(10):3431–3439.
- van der Marel AP, Samsom JN, Greuter M, et al. Blockade of IDO inhibits nasal tolerance induction. J Immunol 2007;179(2):894–900. doi:https://doi.org/10.4049/jimmunol.179.2.894.
- Matteoli G, Mazzini E, Iliev ID, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010;59(5):595–604. doi:https://doi.org/10.1136/gut.2009.185108.
- Desvignes L, Ernst JD. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 2009;31(6):974–985. doi:https://doi.org/10.1016/j.immuni.2009.10.007.
- Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008;451(7175):211–215. doi:https://doi.org/10.1038/nature06471.
- Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010;2(32):32ra36–32rra6.
- Widner B, Sepp N, Kowald E, et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000;201(5):621–630.
- Merlo LM, Mandik-Nayak L. IDO2: a pathogenic mediator of inflammatory autoimmunity. Clin Med Insights Pathol 2016;9(Suppl 1):21–28.
- Gurtner GJ, Newberry RD, Schloemann SR, et al. Inhibition of indoleamine 2, 3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003;125(6):1762–1773.
- Sakurai K, Zou J-P, Tschetter JR, et al. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;129(1–2):186–196.
- Szántó S, Koreny T, Mikecz K, et al. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther 2007;9(3):R50.
- Scott GN, DuHadaway J, Pigott E, et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009;182(12):7509–7517.
- Von Bubnoff D, Bieber T. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy 2012;67(6):718–725. doi:https://doi.org/10.1111/j.1398-9995.2012.02830.x.
- Criado G, Šimelyte E, Inglis JJ, et al. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum 2009;60(5):1342–1351. doi:https://doi.org/10.1002/art.24446.
- Seo SK, Choi JH, Kim YH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004;10(10):1088–1094. doi:https://doi.org/10.1038/nm1107.
- Xu H, Oriss TB, Fei M, et al. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci USA 2008;105(18):6690–6695. doi:https://doi.org/10.1073/pnas.0708809105.
- Pertovaara M, Hasan T, Raitala A, et al. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 2007;150(2):274–278. doi:https://doi.org/10.1111/j.1365-2249.2007.03480.x.
- Schroecksnadel K, Winkler C, Duftner C, et al. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 2006;25(3):334–337.
- Dolusić E, Larrieu P, Moineaux L, et al. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem 2011;54(15):5320–5334. doi:https://doi.org/10.1021/jm2006782.
- Sun J-X, Zhang W-G, Chen Y-X, et al. Indoleamine 2, 3-dioxygenase expression in cells of human acute monocyte leukemia (M (5)) and acute lymphocyte leukemia and therapeutic effect of its inhibitor 1-methyl tryptophan. Zhongguo Shi Yan Xue ye Xue za Zhi 2007;15(3):478–482.
- Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9(10):1269–1274. doi:https://doi.org/10.1038/nm934.
- Schroecksnadel K, Winkler C, Fuith LC, et al. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005;223(2):323–329.
- Corm S, Berthon C, Imbenotte M, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res 2009;33(3):490–494.
- Ino K, Yamamoto E, Shibata K, et al. Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008;14(8):2310–2317.
- Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006;12(4):1144–1151.
- Weinlich G, Murr C, Richardsen L, et al. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007;214(1):8–14.
- Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 2005;7(4):390–396. doi:https://doi.org/10.1593/neo.04658.
- Takao M, Okamoto A, Nikaido T, et al. Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17(6):1333–1339.
- Okamoto A, Nikaido T, Ochiai K, et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005;11(16):6030–6039. doi:https://doi.org/10.1158/1078-0432.CCR-04-2671.
- Watkins SK, Zhu Z, Riboldi E, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011;121(4):1361–1372.
- Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4(12):1206–1212. doi:https://doi.org/10.1038/ni1003.
- Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114(2):280–290.
- Jonuleit H, Schmitt E, Steinbrink K, et al. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22(7):394–400.
- Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297(5588):1867–1870. doi:https://doi.org/10.1126/science.1073514.
- Sioud M, Saebøe-Larssen S, Hetland TE, et al. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients. Int J Oncol 2013;43(1):280–288. doi:https://doi.org/10.3892/ijo.2013.1922.
- Flatekval GF, Sioud M. Modulation of dendritic cell maturation and function with mono‐and bifunctional small interfering RNAs targeting indoleamine 2, 3‐dioxygenase. Immunology 2009;128(Suppl 1):e837–e848.
- Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017;45(W1):W98–W102.
- Hascitha J, Priya R, Jayavelu S, et al. Analysis of kynurenine/tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients. Clin Biochem 2016;49(12):919–924.
- Zhai L, Ladomersky E, Lauing KL, et al. Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clin Cancer Res 2017;23(21):6650–6660. doi:https://doi.org/10.1158/1078-0432.CCR-17-0120.
- Xin Y, Cai H. Improved radiosynthesis and biological evaluations of L- and D-1-[18F]fluoroethyl-tryptophan for PET imaging of IDO-mediated kynurenine pathway of tryptophan metabolism. Mol Imaging Biol 2017;19(4):589–598. doi:https://doi.org/10.1007/s11307-016-1024-z.
- Henrottin J, Lemaire C, Egrise D, et al. Fully automated radiosynthesis of N(1)-[(18)F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging. Nucl Med Biol 2016;43(6):379–389. doi:https://doi.org/10.1016/j.nucmedbio.2016.03.001.
- Qin Y, Ekmekcioglu S, Forget M-A, et al. Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators. Front Immunol 2017;8:689. doi:https://doi.org/10.3389/fimmu.2017.00689.
- Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol 2016;37(3):193–207. doi:https://doi.org/10.1016/j.it.2016.01.002.
- Routy J-P, Routy B, Graziani GM, et al. The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy. Int J Tryptophan Res 2016;9:67–77.
- Zhai L, Spranger S, Binder DC, et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res 2015;21(24):5427–5433. doi:https://doi.org/10.1158/1078-0432.CCR-15-0420.
- Barton Beverly E. IDO: a target for cancer treatment 2014. Available from: http://www.personalizedmedonc.com/publications/ito/june-2014-part-2/ido-a-target-for-cancer-treatment/.
- Hornyák L, Dobos N, Koncz G, et al. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol 2018;9:151. doi:https://doi.org/10.3389/fimmu.2018.00151.
- Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014;2(1):3.
- Nakashima H, Ikkyu K, Nakashima K, et al. Design of novel hypoxia-targeting IDO hybrid inhibitors conjugated with an unsubstituted L-TRP as an IDO affinity moiety. Adv Exp Med Biol. 2010;662:415–421.
- Hou D-Y, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67(2):792–801.
- Holmgaard RB, Zamarin D, Munn DH, et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013;210(7):1389–1402. doi:https://doi.org/10.1084/jem.20130066.
- Wainwright D, Chang A, Dey M, et al. Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 2015;21(3):662.
- Holmgaard RB, Zamarin D, Li Y, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 2015;13(2):412–424. doi:https://doi.org/10.1016/j.celrep.2015.08.077.
- Metz R, Rust S, DuHadaway JB, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 2012;1(9):1460–1468. doi:https://doi.org/10.4161/onci.21716.
- Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010;115(17):3520–3530.
- Koblish HK, Hansbury MJ, Bowman KJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors . Mol Cancer Ther 2010;9(2):489–498. doi:https://doi.org/10.1158/1535-7163.MCT-09-0628.
- Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors. Clin Cancer Res 2019;25(11):3220–3228. doi:https://doi.org/10.1158/1078-0432.CCR-18-2740.
- Mautino MR, Jaipuri FA, Waldo J, et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 491. doi:https://doi.org/10.1158/1538-7445.AM2013-491.
- Iversen TZ, Engell-Noerregaard L, Ellebaek E, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2014;20(1):221–232. doi:https://doi.org/10.1158/1078-0432.CCR-13-1560.
- Sharabi A, Tsokos MG, Ding Y, et al. Regulatory T cells in the treatment of disease. Nat Rev Drug Discov 2018;17(11):823–844.
- Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. AJ Transl Med. 2011;9:196–200.
- Sharma MD, Hou D-Y, Liu Y, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009;113(24):6102–6111.
- Liu Y, Liang X, Yin X, et al. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells. Nat Commun 2017;8:15207. doi:https://doi.org/10.1038/ncomms15207.
- Foy J-P, Bertolus C, Michallet M-C, et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol 2017;28(8):1934–1941. doi:https://doi.org/10.1093/annonc/mdx210.
- Garg AD, Vandenberk L, Van Woensel M, et al. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology 2017;6(4):e1295903.
- Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014;3(10):e957994.
- Blache CA, Manuel ER, Kaltcheva TI, et al. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res 2012;72(24):6447–6456.
- Manuel ER, Diamond DJ. A road less traveled paved by IDO silencing: harnessing the antitumor activity of neutrophils. Oncoimmunology 2013;2(3):e23322.
- Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin Cancer Res 2019;25(5):1462–1471. doi:https://doi.org/10.1158/1078-0432.CCR-18-2882.
- Erik LB, Adams J, Essmann M, et al. Indoximod modulates AhR-driven transcription of genes that control immune function [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3753. doi:https://doi.org/10.1158/1538-7445.AM2018-3753.
- Cheong JE, Sun L. Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities. Trends Pharmacol Sci 2018;39(3):307–325. doi:https://doi.org/10.1016/j.tips.2017.11.007.
- Zhang M, Stone E, Triplett TA, et al. A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1–5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5570. doi:https://doi.org/10.1158/1538-7445.AM2017-5570.
- Günther J, Däbritz J, Wirthgen E. Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment. Frontiers in immunology 2019;10:1801–1808.
- Lamas B, Natividad JM, Sokol H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol 2018;11(4):1024–1038. doi:https://doi.org/10.1038/s41385-018-0019-2.
- Anderson G, Maes M. Interactions of tryptophan and its catabolites with melatonin and the alpha 7 nicotinic receptor in central nervous system and psychiatric disorders: role of the aryl hydrocarbon receptor and direct mitochondria regulation. Int J Tryptophan Res 2017;10:1178646917691738. doi:https://doi.org/10.1177/1178646917691738.
- Yoon MS, Choi CS. The role of amino acid-induced mammalian target of rapamycin complex 1(mTORC1) signaling in insulin resistance. Exp Mol Med 2016;48(1):e201.
- Floyd M, El Osta B, Tang SC. First report of Parkinsonism associated with indoximod, an immune-modulating agent. J Glob Oncol 2018;4:1–2. doi:https://doi.org/10.1200/JGO.2016.007492.
- Komrokji RS, Wei S, Mailloux AW, et al. A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2019;19(3):157–161.
- Naour Galluzzi LJ, Zitvogel L, Kroemer L, et al. Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 2020;9(1):1777625.
- Gibney GT, Hamid O, Lutzky J, et al. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer 2019;7(1):80. doi:https://doi.org/10.1186/s40425-019-0562-8.
- Bahary N, Wang-Gillam A, Haraldsdottir S, et al. Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. J Clin Oncol 2018;36(15 Suppl):abstr 4015.
- Leonardi GC, Candido S, Falzone L, et al. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol 2020;57(3):609–618. doi:https://doi.org/10.3892/ijo.2020.5088.